Table 1.

Eligibility criteria in CAR-T studies treating adults with non-Hodgkin’s lymphoma or B-cell lymphoma (N = 15)

Intervention	N (%)
Yescarta (Axicabtagene ciloleucel)	2 (13.3)
Kymriah (Tisagenlecleucel)	1 (6.7)
CD19- or CD20-type CAR-T cell intervention	12 (80.0)
Study type
Single-arm trial of one intervention	12 (80.0)
Multi-arm trial with multiple doses of same intervention	3 (20.0)
Demographic eligibility criteria
Specified an age criteria	12 (80.0)
Clinical eligibility criteria
No comorbidity that would interfere with treatment/assessment	14 (93.3)
Refractory/prior treatment	13 (86.7)
Not pregnant/contraception use	10 (66.7)
CD19 or 20 expression	9 (60.0)
Given life expectancy	8 (53.3)
Adequate cognition/understanding of treatment	5 (33.3)
No prior CAR-T or gene therapy	4 (26.7)
No prior stem cell transplant	4 (26.7)